Mounjaro Questions and Answers: What Patients Ask Most

You've read the headline figures, but how does tirzepatide actually produce that weight loss?

Most weight-loss coverage focuses on the trial percentages and skips the mechanism. Tirzepatide activates two gut-hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both are involved in appetite regulation and blood-sugar control. When both pathways are engaged, the brain receives stronger signals of fullness, the stomach empties more slowly, and the urge to eat between meals tends to diminish. This is the dual-agonist action that sets Mounjaro apart from medicines that work on only one of those receptors.

The practical result most patients describe is not dramatic nausea or willpower, it's a quieter relationship with food. Portion sizes feel more natural to reduce. The SURMOUNT-1 trial, published in the New England Journal of Medicine, recorded average weight reductions of around 20–21% over 72 weeks at the 15 mg maintenance dose, in a study involving over 2,500 adults with obesity. That figure sits in clinical context, not a marketing claim: individual results vary, diet and activity still matter, and no outcome is guaranteed.

Mounjaro is a Black Triangle (▼) medicine, which means the MHRA continues to collect and review safety data actively. That's normal for newer medicines and worth understanding, not alarming. If you'd like the full mechanism detail, the tirzepatide overview covers the pharmacology without the jargon.

The eligibility question most people find confusing: BMI numbers, conditions, and what actually counts

The licensed threshold for Mounjaro in the UK is a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition. Conditions that count include type 2 diabetes, prediabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea, and cardiovascular disease, among others. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance, reflecting differences in cardiometabolic risk at a given BMI.

A BMI figure alone, though, is the start of the conversation rather than the end of it. A prescriber looks at the whole picture: your medical history, current medications, any contraindications, and your circumstances. Pregnancy, breastfeeding, and trying to conceive are situations where Mounjaro is not recommended. It is not licensed for under-18s. Certain conditions (including a personal or family history of medullary thyroid carcinoma or MEN2) require careful discussion before any decision is made.

If you're unsure where you stand, the quickest honest answer is to run through a formal consultation rather than trying to self-assess from a checklist. Our Mounjaro questionnaire is the starting point for that process at nume, and it's reviewed by a GPhC-registered Independent Prescriber the same day.

Side effects: the questions patients feel awkward asking

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping. They tend to be most noticeable in the first days after starting or after a dose increase, and usually settle within a week or two as the body adjusts. Fatigue, headache, and mild dizziness are also reported. Injection-site reactions are possible but generally minor.

Two things patients are less likely to ask upfront but should know: first, if GI symptoms are severe enough to cause dehydration, that needs medical attention promptly, not waiting out. Second, the MHRA has highlighted acute pancreatitis as an infrequent but serious risk associated with GLP-1 medicines generally, severe stomach pain that radiates to the back, with or without vomiting, is a reason to seek urgent care rather than assume it will pass. You can find more detail on the NHS tirzepatide medicine page.

A practical note on storage that trips people up: Mounjaro pens need to be kept refrigerated at 2–8°C. The pen lives in the fridge, which is simple enough, just don't leave it in the fridge door where temperatures fluctuate most. There is a limited window for room-temperature use, but the Patient Information Leaflet states the exact figures and those are the ones to follow, not a number from a forum. Questions about interactions with other medicines (including the oral contraceptive pill, which can have reduced absorption in the early weeks of tirzepatide treatment) are covered in detail on our page about Mounjaro and other medications. If you've also noticed a stuffy nose since starting treatment, our page on Mounjaro and nasal congestion explains why that can happen and what to do about it.

Cost, NHS access, and what private prescription actually means

Mounjaro is available on the NHS, but access is phased and criteria are strict. From around June 2026, the second NHS cohort opened to adults with a BMI of 35–39.9 alongside four or more qualifying conditions. GP practices can now prescribe under the 2026/27 contract, though participation varies by practice. If you meet NHS criteria and your practice is participating, that route is worth exploring. If you don't meet them, or you'd prefer not to wait, a private prescription from a regulated online pharmacy is the legal alternative, provided it follows a genuine clinical assessment.

Private pricing for Mounjaro has changed since Eli Lilly revised its UK list price in September 2025; a factual breakdown of what that means for patients is on our Eli Lilly Mounjaro price increase page. At nume, one transparent price covers consultation, prescription, medicine, and free next-working-day tracked delivery. We're not the cheapest option available, that's a deliberate choice, not an oversight. For a prescription medicine, the cheapest listing answers the wrong question. What matters is genuine supply chain, real clinical oversight, and a pharmacy you can verify.

You can verify any online pharmacy on the GPhC register at pharmacyregulation.org, our registration number is 9012878. If a supplier is offering these medicines without any clinical assessment, that's a serious red flag; the MHRA has seized millions of doses of counterfeit weight-loss pens from unregulated sellers. More on what to look out for is covered in our FAQs.

If reading through these questions and answers has moved things from abstract interest to something more concrete, and you have further questions before taking the next step, our Mounjaro questions page covers the things people most commonly want to know before starting. Check your eligibility and our prescribers will review your answers the same day.